MCK Q1 growth and Precision Medicine Group acquisition lift outlook
MCK cited strong Q1 growth across key segments, with AI and automation driving productivity. Strategy highlights oncology/biopharma/supply chain and the $2.25B Precision Medicine Group acquisition.
Strategy focuses on oncology, biopharma, and supply chain, highlighted by the $2.25B Precision Medicine Group acquisition. Q1 delivered strong growth across key segments, with AI and automation driving productivity. Stable generics, biosimilar opportunities, and disciplined capital deployment suppo…